We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Cost-Effective Method Detects Chikungunya virus

By LabMedica International staff writers
Posted on 05 Aug 2013
The use of capillary blood samples blotted on filter papers for molecular diagnosis of Chikungunya virus (CHIKV) infection has been evaluated. More...


Venous blood samples can be difficult to obtain for the diagnosis of CHIKV and the shipment of serum in appropriate temperature conditions is too costly for most developing countries.

Scientists at the Institut Pasteur de Madagascar (Antananarivo, Madagascar) collected samples from all patients, visiting sentinel centers, that fulfilled the case definition for dengue-like illness with onset within the previous five days were included in the study. Both venous blood and capillary blood were collected and spotted onto a clean Whatman 3MM filter paper (Sigma-Aldrich; St. Louis, MO, USA).

All samples were tested by real-time polymerase chain reaction (RT-PCR) and results with serum and dried-blood blotted on filter paper (DBFP) samples were compared for each patient. CHIKV ribonucleic acid (RNA) was detected by one-step real-time RT-PCR assays in a Rotorgene 6000 apparatus (Corbett Life Science; Mortlake, NSW, Australia; www.corbettlifescience.com).


Overall, 181 samples from patients presenting dengue-like illness were included in the study: 73 (40.3%) were CHIKV confirmed cases and 108 (59.7%) were negative controls; the median age was 18 years and 32 years, and sex ratio (M/F) were 1.2 and 0.5, respectively. Among the 181 patients tested, DBFP for 74 (40.9%) and sera for 73 (40.3%) scored positive for CHIKV. The sensitivity and specificity of tests performed with DBFP were very similar to those with venous samples. The loss of sensitivity was insignificant and involved a very small number of patients, all with low viral loads.

The authors concluded that DBFP is a cost-effective method for surveillance and for the monitoring of viral outbreaks in low-income countries, and especially in large countries where the access to laboratory facilities is limited. This method can facilitate the extension of surveillance system networks, and may be useful to public health authorities for rapid identification of Chikungunya outbreaks and, by extension, those of other arboviruses, such as Dengue fever, Rift Valley Fever, West Nile. The study was published on July 25, 2013, in the journal Public Library of Science Neglected Tropical Diseases.

Related Links:

Institut Pasteur de Madagascar
Sigma-Aldrich
Corbett life science




Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Hybrid Pipette
SWITCH
Gold Member
Collection and Transport System
PurSafe Plus®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The addition of Biocare’s complementary IHC antibody, reagent and instrument portfolio enhances Agilent’s immunohistochemistry offering (Photo courtesy of Biocare Medical)

Agilent Technologies Acquires Pathology Diagnostics Company Biocare Medical

Agilent Technologies (Santa Clara, CA, USA) has entered into a definitive agreement to acquire Biocare Medical (Pacheco, CA, USA), expanding its pathology portfolio through the addition of highly complementary... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.